Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBW2 Vaccine in Advanced Malignant Melanoma
NCT02203864Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 1998
- Primary completion
- Feb 2001
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label trial of BIBW2 in Malignant Melanoma (MM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose Limiting Toxicity up to 6 weeks and Adverse Events. Started Aug 1998; status: completed.
02
Drugs
BIBW2
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT02203864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02203864.